Does body mass index influence improvement in patient reported outcomes following total knee arthroplasty? A retrospective analysis of 3918 cases

Table 6 Multiple linear regression analysis of patient comorbidities and demographics impacting postoperative and pre/post-change (Δ) PROMIS-PH scores

Baseline variable	Postoperative PROMIS GH estimate effect		Δ PROMIS GH estimate effect
Baseline variable	Estimate [95% CI]	P-value	Estimate [95% CI]	P-value
Age (years)	0.1 [0.01: 0.1]	0.009	0.01 [− 0.03: 0.05]	0.562
Female	− 1.8 [− 2.5: −1.1]	< 0.001	0.7 [− 0.03: 1.5]	0.061
BMI 18.5–25 kg/m² (reference)	1.0		1.0
BMI 25.01–30 kg/m²	− 0.6 [− 1.7: 0.5]	0.293	0.6 [− 0.6: 1.8]	0.341
BMI 30.01–40 kg/m²	− 1.5 [− 2.5: − 0.5]	0.005	1.6 [0.4: 2.7]	0.007
BMI > 40 kg/m²	− 2.1 [− 3.4: − 0.8]	0.002	3.0 [1.6: 4.4]	< 0.001
White (reference)	1.0		1.0
African-American (Black)	− 1.7 [− 2.6: − 0.8]	< 0.001	− 0.1 [− 1.1: 0.8]	0.800
Asian	− 2.4 [− 3.9: − 0.8]	0.003	1.0 [− 0.6: 2.6]	0.211
Other Race	− 3.0 [− 3.9: − 2.1]	< 0.001	1.2 [0.2: 2.2]	0.018
Myocardial Infarction	− 1.6 [− 3.8: 0.5]	0.129	− 0.3 [− 2.6: 2.1]	0.829
Cerebrovascular disease	− 0.4 [− 1.5: 0.8]	0.542	− 0.4 [− 1.7: 0.9]	0.522
Chronic Pulmonary Disease	− 1.0 [− 1.8: − 0.2]	0.014	− 0.4 [− 1.3: 0.5]	0.375
Mild Liver Disease	− 0.7 [− 2.2: 0.7]	0.328	− 0.3 [− 1.9: 1.2]	0.682
DM without chronic complications	− 1.6 [− 2.4: − 0.7]	< 0.001	− 0.1 [− 1.0: 0.9]	0.887
DM with chronic complications	− 1.9 [− 3.7: 0.0]	0.049	− 0.8 [− 2.9: 1.3]	0.464
Malignancy lymphoma leukemia	0.2 [− 0.8: 1.2]	0.683	0.1 [− 1.0: 1.2]	0.894
Metastatic solid tumor	− 0.3 [− 2.0: 1.3]	0.698	− 1.1 [− 2.9: 0.6]	0.211

Bold indicates statistical significance
BMI body mass index, PROMIS Patient-Reported Outcome Measurement Information System, Global PH Global Physical Health, DM diabetes mellitus, CI confidence interval

ISSN: 2234-2451